Thalidomide and multiple myeloma: therapy evaluation using clinical and laboratorial parameters

Autor: Laura Fogliato, Henrique Bittencourt, Flavo Beno Fernandes, Andréia Dias Almeida, Claudia Caceres Astigarraga, João R. Friederich, Rosane Bittencourt, Tor Onsten, Alessandra Aparecida Paz, Lucia Mariano da Rocha Silla

Publikováno v: Revista Brasileira de Hematologia e Hemoterapia, Volume: 26, Issue: 4, Pages: 245-255, Published: DEC 2004
Revista Brasileira de Hematologia e Hemoterapia v.26 n.4 2004
Revista brasileira de hematologia e hemoterapia
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
instacron:ABHHTC

Nas duas últimas décadas, houve uma mudança radical na terapia e na evolução do mieloma múltiplo(MM), neoplasia hematológica ainda considerada fatal. As pesquisas e investimentos em medicamentos que interferem com a fisiopatogenia e com o micr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fae6af656a5ae28cb8075818ed55ccb5
https://doi.org/10.1590/s1516-84842004000400004

The Role of Early Cytogenetic Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib and the Impact of Adherence and Comorbidities

Autor: Saozan Ahmad, Sabrina Wisintainer, Viviane Magagnin Fernandes, Mariangela Moschen, Moema Nene, Mariza Shaan, Mario Sérgio Fernandes, Tito Vanelli Costa, Tiago Daltoe, Laura Fogliatto, Marco Antônio Schilling, Juliana Kratochvil, Cheila Eickhoff, Andréia Dias Almeida, Tânia Hellwig, Marcelo Capra, Adriana Zardo, Virginia Maria Coser, Márcia Leite, Lucia Mariano da Rocha Silla, Dayane Bohn Koshiyama, Denise Almeida, Waldir Veiga Pereira, Katia Fassina, Liane Esteves Daudt, Nathália Guterres Xavier, Dalnei Veiga Pereira, Vitor Lenz, Mayde Seadi Torriani

Publikováno v: Blood. 118:4423-4423

Abstract 4423 Background Treatment of chronic myeloid leukemia with imatinib leads to disease remission in a majority of patient, but in some patients (pts) controlling the disease remains a challenge. One of the proposed prognostic factors for ident

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2c7e7b2ed6e88ea21230d2eb7938cc2f
https://doi.org/10.1182/blood.v118.21.4423.4423

Results of Imatinib Therapy In Patients with Early and Late Chronic-Phase Chronic Myeloid Leukemia In a South Brazilian Cohort

Autor: Gilca Nachtigal, Marco Antônio Schilling, Andréia Dias Almeida, Tito Vanelli Costa, Moema Nene, Erica Lammerhirt Ottoni, Marcelo Capra, Tânia Hellwig, Liane Esteves Daudt, Mayde Seadi Torriani, Laura Fogliatto, Mario Sérgio Fernandes, Mariza Shaan, Christina G S Fraga, Katia Fassina, Lucia Mariano da Rocha Silla, Adriana Zardo, Denise Almeida

Publikováno v: Blood. 116:4487-4487

Abstract 4487 Background: Imatinib treatment for Chronic Myeloid Leukemia (CML) was first introduced in Brazil in 2001, initially used as second line therapy for patients resistant or intolerant to interferon (IFN). In 2008 imatinib was adopted as fr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6764e77c733969bd19924c0b7fef044b
https://doi.org/10.1182/blood.v116.21.4487.4487

Low Dose Thalidomide for the Treatment of Multiple Myeloma

Autor: Rosane Bittencourt, Andréia Dias Almeida, Laura Fogliatto, Lucia Mariano da Rocha Silla, Denise Leugeur, João R. Friederich, Flavo Fernande, Claudia Caceres Astigarraga, Alessandra Aparecida Paz

Publikováno v: Blood. 106:5146-5146

In the last two decades, we have seen a radical change in the therapy and prognosis of Multiple Myeloma (MM). Recent research on the role of the bone marrow microenvironment as integrant part of the biology of MM and the possible therapeutic interfer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::973910ce93f2d968d18c546298c5f685
https://doi.org/10.1182/blood.v106.11.5146.5146